31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million

Transcription

1

2 31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million cancer cases Adult patients (age 15+) 45 major cancer sites Diagnosis Follow-up 2008 or later Uniform data collection protocol and statistical analyses

3 13 scientific articles Country-specific survival Adult patients (age 15+) Survival by cancer site or system Analyses by subsite, tumour morphology, stage Time trends incidence and survival Statistical methodology

4 Prostate Non Hodgkin lymphoma Rectum difference Kidney Breast Colon

5

6 Denmark Finland Iceland Norway Sweden Ireland UK, England UK, Northern Ireland UK, Scotland UK, Wales Austria Belgium France Germany Switzerland The Netherlands Croatia Italy Malta Portugal Slovenia Spain Bulgaria Czech Republic Estonia Latvia Lithuania Poland Slovakia Northern Europe Ireland and UK Central Europe Southern Europe Eastern Europe 59,4 (59,0 59,7)

7 Denmark Finland Iceland Norway Sweden Ireland UK, England UK, Northern Ireland UK, Scotland UK, Wales Austria Belgium France Germany Switzerland The Netherlands Croatia Italy Portugal Slovenia Spain Bulgaria Czech Republic Estonia Latvia Lithuania Poland Slovakia Northern Europe Ireland and UK Central Europe Southern Europe Eastern Europe 52,9 (51,6 54,2)

8 Hodgkin's lymphoma Follicular lymphoma Chronic lymphocytic leukaemia/ small lymphocytic lymphoma Diffuse Large B-cell lymphoma Chronic myeloid leukaemia 40 Multiple myeloma

9 Denmark Finland Iceland Norway Sweden Ireland UK England UK Northern Ireland UK Scotland UK Wales Austria Belgium France Germany Switzerland The Netherlands Croatia Italy Malta Portugal Slovenia Spain Bulgaria Czech Republic Estonia Latvia Lithuania Poland Slovakia Northern Europe Ireland and UK Central Europe Southern Europe Eastern Europe ,8 (55,5-56,1)

10 Northern Europe Ireland and UK Central Europe Southern Europe Eastern Europe Europe

11 Denmark Finland Iceland Norway Sweden Ireland UK, England UK, Northern Ireland UK, Scotland UK, Wales Austria Belgium France Germany Switzerland The Netherlands Croatia Italy Malta Portugal Slovenia Spain Bulgaria Czech Republic Estonia Latvia Lithuania Poland Slovakia Northern Europe Ireland and UK Central Europe Southern Europe Eastern Europe 83,2 (82,9-83,6)

12 Lentigo_maligna Superficial_spread In_nevo NOS Epitelial Nodular Non_pigment patients diagnosed in , FOLLOWED UP TO EUROCARE REGISTRIES

13 Northern Ireland and UK Central Europe Southern Eastern Europe (antrum, pylorum, lesser curvature) (cardias, fundus, lesser curvature)

14

15 Aver age TNEH p er cap it e $ Pur ch asin g Po w er Par it y $3,500 $3,000 $2,500 R 2 log-linear regression 73% $2,000 $1,500 $1,000 $500 $- BG, LV, PL, SK, LT, EE, SL, UK, DK CR, CZ, MT, IE, NL, ES, NO, FR, PT CH, FI, BE, IT, SE, DE, AT, IS [39% -49% ) [49% -55% ) [55% -58% ) 5-y relative survival tertiles for all cancer cases diagnosed in

16 EUROCARE -5 KEY MESSAGES Improvements in cancer survival over time, but persisting variations across countries and regions point inequalities in cancer care Related to: differences in cancer biology (stomach, head & neck) diagnostic intensity and screening, leading to earlier stage at diagnosis (breast, colorectal, prostate) effective treatments (NHL and CML) socioeconomic status, lifestyle and general health differences between populations Further investigations needed on: tumour characterisation co-morbidity and its influence on the prognosis survivorship cancer costs and organization of care

17 To help reduce survival inequalities & improve cancer care Reduction in the fragmentation of care services Promotion of comprehensive multidisciplinary cancer care centres Better organisation and funding of health care systems Promotion and funding outcome research Alliance between patients, physicians and researchers

18 Research based on population-based disease registries, shall not be impeded by the proposal on the General Data Protection Regulation exemption from patient consent is necessary, to permit the collection of complete, accurate, high quality data needed to develop evidence-based policy decisions measure their effectiveness

19